Back to search results
David Oh
David Oh

David Oh, MD, PhD

Urologic Oncology

Cancer Immunotherapy Clinic
1825 Fourth St., Fifth Floor,
San Francisco, CA 94158
+2 more locations
(415) 353-2421
Virtual visits available
Virtual visits available
Cancer Immunotherapy Clinic
1825 Fourth St., Fifth Floor,
San Francisco, CA 94158
+2 more locations
(415) 353-2421

Dr. David Oh is a medical oncologist who cares for patients who are receiving novel immunotherapies for cancers as part of clinical trials. These are treatments that harness the patient's own immune system to fight cancer. He specializes in prostate and bladder cancers.

Oh's research focuses on understanding and improving cancer immunotherapies. He leads clinical trials to evaluate new immunotherapies for solid tumors, and he studies samples from patients who have received immunotherapies with the goal of better understanding their benefits and side effects.

Oh earned his medical degree from Stanford University School of Medicine, where he also completed a doctorate in physiology. At UCSF, he completed a residency in internal medicine and a fellowship in hematology and oncology.

Oh is a member of the American Society of Clinical Oncology, American Association for Cancer Research and Society for Immunotherapy of Cancer. He has received Young Investigator Awards from the Prostate Cancer Foundation, Bladder Cancer Advocacy Network and Conquer Cancer Foundation of the American Society of Clinical Oncology.

  • Board Certifications

    American Board of Internal Medicine, Medical Oncology, 2017

    American Board of Internal Medicine, Internal Medicine, 2014

  • Fellowships

    UCSF, Hematology - Oncology, 2017

  • Residencies

    UCSF, Internal Medicine, 2014

  • Internship

    UCSF, Internal Medicine, 2012

  • Degree

    Stanford University School of Medicine, 2011

  • Languages

    English

I am committed to offering the latest immunotherapies to all cancer patients, and helping each patient find the kind of clinical trial that is the best fit for them.

Where I see patients (3)

    Selected research

    See all research
    Decorative Caduceus

    A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

    Rate of dose-limiting toxicities (DLTs) after infusion of CLSP-1025

    Recruiting

    Decorative Caduceus

    Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior ...

    A positive response is defined as a ≥40% increase in the number of infiltrating cluster of differentiation 3 (CD3) + T cells between the pre-treatment biopsy at baseline and the post-treatment RP specimen. Thus, a negative respons...

    Recruiting

    Decorative Caduceus

    Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell C...

    Recruiting

    Contact me

    Share